Ämnen: Vetenskap, teknik

FDA GRANTS PRIORITY REVIEW TO PLAVIXÒ (clopidogrel bisulfate) SUPPLEMENTAL NEW DRUG APPLICATION (sNDA) FOR ADDITIONAL TYPE OF HEART ATTACK

18 Januari 2006 13:42

Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental new drug application (sNDA) for the antiplatelet agent PLAVIX® (clopidogrel bisulfate) for treatment of patients with acute STsegment elevation myocardial infarction (STEMI).

SANOFI PASTEUR ANNOUNCES PRELIMINARY TRIAL RESULTS FOR A FIRST H5N1 PRE-PANDEMIC INFLUENZA VACCINE CANDIDATE WITH AN ADJUVANT

15 December 2005 09:32

Vice President Communications sanofi pasteur: Alain BERNAL – U. S. Media Relations: Len LAVENDA Tel.: +1 570 839 7187 - Fax: +1 570 839 0955 - Sanofi Pasteur Inc. - Discovery Drive - Swiftwater, PA 18370-0187 - USA - www.sanofipasteur.com ~ Data Show that the Vaccine Is Safe, Demonstrates Immunogenicity and Provides Future Direction For Development ~ Lyon, France – December 15, 2005 – Sano

INTERIM ANALYSIS OF PHASE III STUDY SHOWS TAXOTERE®-BASED REGIMENS WITH HERCEPTIN® SIGNIFICANTLY IMPROVED DISEASE FREE SURVIVAL IN WOMEN WITH EARLY-STAGE HER2-POSITIVE BREAST CANCER

8 December 2005 16:53

Results from the BCIRG 006 study also show that a novel non-anthracycline-based regimen (“TCH”) with TAXOTERE® (docetaxel), the platinum salt carboplatin and HERCEPTIN® (trastuzumab) reduces the risk of recurrence without increasing cardiotoxicity in patients with early stage HER2-positive breast cancer Paris and San Antonio – December 8th, 2005 – The Breast Cancer International Research Group

NEW ENGLAND JOURNAL OF MEDICINE PUBLICERAR RIO-LIPIDS-STUDIEN

17 November 2005 15:53

Studie visar att rimonabant signifikant reducerar kardiovaskulära och metabola riskfaktorer hos överviktiga och feta patienter Paris, Frankrike, 16 november 2005 – Sanofi-aventis tillkännagav att resultaten från RIO-Lipidsstudien publicerades i dag i The New England Journal of Medicine. I studien undersöktes effekten av rimonabant hos patienter med övervikt och fetma samt avvikande blodfetter (

INTERNATIONELL DIABETESUNDERSÖKNING BELYSER ATT PERSONER MED DIABETES OCH VÅRDGIVARE HAR OLIKA UPPFATTNINGAR OM SJUKDOMEN OCH HUR DEN SKA BEHANDLAS

14 November 2005 13:32

En stor undersökning som publiceras på World Diabetes Day 14 november 2005 visar att diabetiker i större utsträckning vill medverka vid beslut som rör behandlingen av sjukdomen. Paris, 14 november 2005 – Resultaten av en undersökning som publiceras idag på World Diabetes Day visar att nästan 80% av allmänheten personligen känner någon som har diabetes. För närvarande finns fler än 194 miljon

SANOFI PASTEUR SIGNS CONTRACT WITH FRENCH GOVERNMENT TO PRODUCE PANDEMIC INFLUENZA VACCINE

10 November 2005 10:19

Alain BERNAL Vice-President Corporate Communications Tel: + 33-(0)4-37-37-78-97 Fax: +33-(0)4-37-37-77 89 Len LAVENDA U.S. Media Relations Tel: +1-570-839-4446 Len.Lavenda@sanofipasteur.com ~ Influenza Vaccine Leader sanofi Pasteur Contributes to French Pandemic Preparedness ~ Lyon, France – November 10, 2005 – Following discussions which started a few months ago, sanofi pasteur,

TELITHROMYCIN AGAINST STREPTOCOCCUS PNEUMONIAE SHOWN SUPERIOR

21 September 2005 09:33

MICROBIOLOGICAL ACTIVITY OF TELITHROMYCIN AGAINST STREPTOCOCCUS PNEUMONIAE SHOWN SUPERIOR TO OTHER STANDARD FIRST LINE ANTIBIOTICS OVER 4-YEAR PERIOD New data demonstrates that in vitro activity of Ketek (telithromycin) remained consistently high on S. pneumoniae with at least 99.8% of the isolates being susceptible Paris, 20 September 2005 – Data presented today at the 15th Annual Internati

TAXOTERE®-BASED CHEMOTHERAPY REGIMENS COMBINED WITH HERCEPTIN® SIGNIFICANTLY IMPROVED DISEASE FREE SURVIVAL IN EARLY-STAGE HER2-POSITIVE BREAST CANCER

15 September 2005 13:41

INTERIM ANALYSIS OF PHASE III STUDY SHOWS TAXOTERE® (docetaxel)- BASED CHEMOTHERAPY REGIMENS COMBINED WITH HERCEPTIN® (trastuzumab) SIGNIFICANTLY IMPROVED DISEASE FREE SURVIVAL IN EARLY-STAGE HER2-POSITIVE BREAST CANCER Interim analysis of more than 3,000 patients in BCIRG006 study also shows TAXOTERE® non-anthracycline-based chemotherapy combined with HERCEPTIN® improved disease-free surviv

DATA AT EASD SUGGESTS BETTER GLYCAEMIC CONTROL POSSIBLE USING INSULIN GLARGINE OR INSULIN GLULISINE IN TYPE 2 DIABETES

15 September 2005 08:55

Studies show impact of enforced titration of Lantus® (insulin glargine) on reducing HbA1C levels, and Apidra® (insulin glulisine) on postprandial glucose control in patients with type 2 diabetes Athens September 14th, 2005: Data presented at the 41st Annual Meeting of the European Association for the Study of Diabetes (EASD), Athens show that a strictly enforced titration schedule with intensiv

A high proportion of hypertensive patients achieved blood pressure treatment goal with irbesartan-based combination therapy, findings show

21 Juni 2005 10:14

Contact: sanofi-aventis Jean Marc Podvin +33 (0)1 53 77 42 23 Salah Mahyaoui +33 (0)1 53 77 40 31 +33 (0)6 73 68 78 88 Bristol-Myers Squibb Rob Hutchinson +1 609 252 3901 +1 609 271 2704 Recent clinical findings have demonstrated that a large majority of hypertensive patients who failed to achieve blood pressure goal on monotherapy can be helped to attain goal with the angiotensin-I

New study results further enhances the role of Eloxatin® in early and advanced stages of colon cancer

18 Maj 2005 14:09

Major data presented at ASCO 2005 on Eloxatin® in combination with other chemotherapeutic drugs and with new targeted agents Paris, France – May 18, 2005 - Sanofi-aventis announced today the results of key trials on the anti-cancer drug Eloxatin® (oxaliplatin for injection), presented at the 2005 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida. The study f

Alfuzosin 10 mg OD (Xatral® OD) visar positiv effekt hos patienter med urinstopp

6 April 2004 10:31

Behovet av BPH-relaterad kirurgi reduceras Resultaten av ALFAUR-studien (ALFuzosin in Acute Urinary Retention), som presenterades vid European Association of Urologys (EAU) kongress i Wien, visar att den uroselektiva alfa1-blockeraren alfuzosin 10 mg en gång dagligen (OD = once daily) kan ha en positiv effekt på behandlingen av män som lider av akut urinretention (AUR). Akut urinretention (u

Ny studie på vanlig hjärtsjukdom hos kvinnor

8 Oktober 2003 11:12

En ny studie ska ge svar på hur en vanlig form av hjärtsvikt kan behandlas. Ungefär hälften av alla patienter med hjärtsvikt har en normal sk. systolisk funktion.